GlassScriptPhysician profile
Asif Cochinwala
NPI 1245212521
$7,427.45
in general payments reported to CMS, 2019-2025
29 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,882 · 2020: $334 · 2021: $384 · 2022: $782 · 2023: $937 · 2024: $1,167 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,033.34 | 2019-2025 | Tremfya |
| Amgen INC. | $1,265.29 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Ucb, INC. | $1,102.13 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $823.33 | 2019-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $505.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $254.11 | 2022-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $237.85 | 2022-2024 | Saphnelo |
| Radius Health, INC. | $215.39 | 2019-2025 | Tymlos |
| Sandoz INC. | $114.33 | 2023-2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.12 | 2019-2024 | Cyltezo |
| Genentech USA, INC. | $75.65 | 2019 | |
| Alvogen INC | $71.39 | 2024-2025 | Teriparatide |
| Lilly USA, LLC | $71.22 | 2019-2023 | Taltz |
| Bioventus LLC | $70.73 | 2019-2025 | Durolane |
| Octapharma USA, INC. | $66.28 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63.77 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.95 | 2019-2020 | |
| Celgene Corporation | $59.82 | 2019 | |
| Aurinia Pharma U.S., INC. | $40.73 | 2023-2024 | Lupkynis |
| Pfizer INC. | $39.80 | 2020-2022 | |
| Biocon Biologics INC | $38.96 | 2024-2025 | Hulio, Yesintek |
| Fresenius Kabi USA, LLC | $28.32 | 2024 | Idacio |
| Merck Sharp & Dohme LLC | $25.72 | 2019-2020 | |
| Mylan Institutional INC. | $20.92 | 2023 | |
| Fidia Pharma USA INC. | $19.68 | 2024 | Hymovis |
| Hikma Pharmaceuticals USA | $16.22 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Cochinwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.